SUPERNUS PHARMACEUTICALS, INC. SUPN
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders.
The Company was incorporated in Delaware, commenced operations in 2005, became publicly traded in 2012, and is listed on the NASDAQ Stock Exchange under the ticker symbol SUPN. Our principal executive offices are located in Rockville, Maryland. Our extensive expertise in product development has been built over the past 30 years: initially as a stand-alone development organization; then, as a United States (U.S.) subsidiary of Shire Plc (Shire, a subsidiary of Takeda Pharmaceutical Company Ltd.); then upon our acquisition of substantially all of the assets of Shire Laboratories, Inc. in 2005, as Supernus Pharmaceuticals, Inc.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M | $520.4M | $392.8M | $408.9M | $302.2M | $215.0M |
| Cost of revenue | $74.6M | $77.9M | $83.8M | $87.2M | — | $52.5M | $16.7M | $15.4M | $15.2M | $12.0M |
| Gross profit | $644.4M | $583.9M | $523.7M | $580.0M | — | $467.9M | $376.1M | $393.5M | $287.0M | $203.0M |
| R&D | $106.2M | $108.8M | $91.6M | $74.6M | $90.5M | $76.0M | $69.1M | $89.2M | $49.6M | $42.8M |
| SG&A | $485.6M | $321.6M | $336.4M | $377.2M | $304.8M | $200.7M | $153.2M | $154.7M | $137.9M | $106.0M |
| Total operating expenses | $781.2M | $580.2M | $612.8M | $621.1M | $493.7M | $346.7M | $244.2M | $264.5M | $202.7M | $160.8M |
| Operating income | -$62.3M | $81.7M | -$5.3M | $46.1M | $86.0M | $173.7M | $148.6M | $144.4M | $99.5M | $54.2M |
| Interest expense | $0 | $0 | $2.4M | $7.1M | $19.7M | $19.4M | $18.2M | $13.8M | $134.0K | $543.0K |
| Pre-tax income | -$49.0M | $97.9M | $2.8M | $60.7M | $73.2M | $168.6M | $147.5M | $140.2M | $100.6M | $50.4M |
| Income tax | $10.5M | $24.0M | $1.5M | $32.0K | $19.8M | $41.7M | $34.4M | $29.2M | $43.3M | $40.9M |
| Net income | -$38.6M | $73.9M | $1.3M | $60.7M | $53.4M | $127.0M | $113.1M | $111.0M | $57.3M | $91.2M |
| EPS, basic | -0.68 | 1.34 | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 |
| EPS, diluted | -0.68 | 1.32 | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 | 2.05 | 1.08 | 1.76 |
| Shares, diluted (wtd. avg.) | $56.5M | $56.0M | $55.5M | $61.7M | $54.4M | $53.7M | $53.8M | $54.1M | $53.3M | $51.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $128.4M | $69.3M | $75.1M | $93.1M | $203.4M | $288.6M | $181.4M | $192.2M | $100.3M | $66.4M |
| Short-term investments | — | — | — | $368.2M | $136.2M | $133.9M | $165.7M | $163.8M | $39.7M | $23.7M |
| Receivables | $187.8M | $142.1M | $144.2M | $165.5M | $148.9M | $140.9M | $87.3M | $102.9M | $67.2M | $41.5M |
| Inventory | $112.5M | $54.3M | $77.4M | $91.5M | $86.0M | $48.3M | $26.6M | $25.7M | $16.3M | $16.8M |
| Total current assets | $644.2M | $686.1M | $493.1M | $734.2M | $601.6M | $630.4M | $472.6M | $493.5M | $228.5M | $151.4M |
| Property, plant and equipment | $10.5M | $11.5M | $13.5M | $15.2M | $17.0M | $37.8M | $17.1M | $4.1M | $5.1M | $4.3M |
| Goodwill | $124.9M | $117.0M | $117.0M | $117.0M | $117.5M | $77.9M | $0 | — | — | — |
| Other intangibles | $569.5M | $521.9M | $599.9M | $702.5M | $784.7M | $364.3M | $24.8M | $31.4M | $36.0M | $36.4M |
| Total assets | $1.45B | $1.37B | $1.28B | $1.70B | $1.69B | $1.50B | $1.16B | $977.8M | $424.5M | $309.6M |
| Accounts payable | $2.7M | $4.6M | $2.0M | $10.5M | $9.3M | $6.1M | $10.1M | $3.2M | $6.8M | $8.1M |
| Total current liabilities | $338.2M | $292.4M | $290.2M | $688.0M | $315.4M | $245.1M | $160.6M | $161.4M | $123.0M | $80.7M |
| Total liabilities | $390.9M | $332.3M | $356.2M | $816.3M | $873.3M | $759.2M | $564.9M | $524.8M | $157.0M | $117.8M |
| Retained earnings | $517.9M | $556.4M | $482.6M | $481.2M | $379.9M | $326.5M | $199.5M | $86.5M | -$26.8M | -$84.3M |
| Total equity | $1.06B | $1.04B | $921.5M | $886.2M | $815.9M | $744.9M | $595.4M | $453.0M | $267.5M | $191.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $47.3M | $172.0M | $111.1M | $116.8M | $127.1M | $138.4M | $143.1M | $129.0M | $114.6M | $66.8M |
| Depreciation and amortisation | $91.6M | $80.4M | $84.9M | $85.5M | $32.6M | $18.1M | $6.7M | $7.1M | $8.1M | $2.4M |
| Stock-based compensation | $33.1M | $27.8M | $26.8M | $17.6M | $17.9M | $16.6M | $14.8M | $11.3M | $8.4M | $5.9M |
| Capital expenditure | $1.3M | $725.0K | $551.0K | $412.0K | — | $3.4M | $2.7M | $844.0K | $2.0M | $1.6M |
| Investing cash flow | $4.1M | -$189.9M | $268.7M | -$216.7M | -$81.9M | -$34.7M | -$157.9M | -$413.5M | -$86.4M | -$36.0M |
| Financing cash flow | $9.1M | $12.2M | -$397.9M | -$10.5M | -$130.4M | $3.6M | $3.9M | $376.4M | $5.7M | $2.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-053111.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |